Ultimately, our in vitro and in vivo experiments have validated that miR-16 inhibited the TLR4/NF-κB pathway, thus repressing XIST to maintain intestinal epithelial tight junction integrity and to relieve IBS. This evidence concerns the gene NFKB1 and irritable bowel syndrome.